Total Payments
$477,330
2024 Payments
$25,521
Companies
35
Transactions
743
Medicare Patients
2,167
Medicare Billing
$341,834
Payment Breakdown by Category
Other$385,449 (80.8%)
Travel$49,686 (10.4%)
Food & Beverage$21,423 (4.5%)
Consulting$20,580 (4.3%)
Education$192.46 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $385,449 | 158 | 80.8% |
| Travel and Lodging | $49,686 | 183 | 10.4% |
| Food and Beverage | $21,423 | 386 | 4.5% |
| Consulting Fee | $20,580 | 12 | 4.3% |
| Education | $192.46 | 4 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $134,688 | 151 | $0 (2021) |
| Esperion Therapeutics, Inc. | $98,101 | 96 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $73,113 | 103 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $58,841 | 72 | $0 (2021) |
| Lilly USA, LLC | $37,649 | 52 | $0 (2024) |
| Amgen Inc. | $26,459 | 37 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $12,939 | 30 | $0 (2024) |
| PFIZER INC. | $10,607 | 22 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $10,286 | 10 | $0 (2019) |
| Merck Sharp & Dohme LLC | $7,001 | 26 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $25,521 | 54 | Boehringer Ingelheim Pharmaceuticals, Inc. ($9,995) |
| 2023 | $41,547 | 64 | Boehringer Ingelheim Pharmaceuticals, Inc. ($20,096) |
| 2022 | $52,868 | 86 | Esperion Therapeutics, Inc. ($20,758) |
| 2021 | $78,703 | 114 | Esperion Therapeutics, Inc. ($52,844) |
| 2020 | $32,117 | 43 | Esperion Therapeutics, Inc. ($18,590) |
| 2019 | $144,191 | 181 | SANOFI-AVENTIS U.S. LLC ($79,798) |
| 2018 | $43,129 | 85 | SANOFI-AVENTIS U.S. LLC ($21,949) |
| 2017 | $59,255 | 116 | SANOFI-AVENTIS U.S. LLC ($27,543) |
All Payment Transactions
743 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $30.81 | General |
| Category: Cardiovascular | ||||||
| 12/16/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $26.25 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 12/11/2024 | BIOTRONIK INC. | BIOMONITOR (Device) | Food and Beverage | In-kind items and services | $37.46 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/03/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $24.65 | General |
| Category: Diabetes | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.81 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $27.29 | General |
| Category: DIABETES | ||||||
| 10/22/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $29.17 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 10/08/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/11/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $36.40 | General |
| Category: Cardiovascular | ||||||
| 09/09/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $24.21 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/28/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $23.35 | General |
| Category: DIABETES | ||||||
| 08/26/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $28.01 | General |
| Category: Not Applicable | ||||||
| 08/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,850.00 | General |
| Category: DIABETES | ||||||
| 08/08/2024 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Cardiology | ||||||
| 08/07/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Travel and Lodging | In-kind items and services | $68.78 | General |
| Category: DIABETES | ||||||
| 08/06/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Cardiology | ||||||
| 07/31/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $25.54 | General |
| Category: DIABETES | ||||||
| 07/29/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: Obesity | ||||||
| 07/25/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,480.00 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 07/17/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $24.90 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/16/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Travel and Lodging | In-kind items and services | $681.70 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 07/16/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Food and Beverage | In-kind items and services | $77.55 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 07/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $118.06 | General |
| Category: DIABETES | ||||||
| 06/12/2024 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $830.00 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 05/22/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,850.00 | General |
| Category: DIABETES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 570 | 833 | $249,958 | $102,331 |
| 2022 | 10 | 486 | 614 | $248,375 | $79,483 |
| 2021 | 10 | 547 | 749 | $307,198 | $78,577 |
| 2020 | 11 | 564 | 990 | $324,323 | $81,443 |
Total Patients
2,167
Total Services
3,186
Medicare Billing
$341,834
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 166 | 297 | $80,190 | $28,837 | 36.0% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 40 | 77 | $38,500 | $27,064 | 70.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 101 | 105 | $44,520 | $15,593 | 35.0% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 40 | 40 | $38,400 | $13,777 | 35.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 54 | 54 | $19,440 | $6,541 | 33.6% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 27 | 108 | $11,880 | $4,643 | 39.1% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 18 | 18 | $7,488 | $2,617 | 35.0% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 46 | 46 | $6,900 | $2,298 | 33.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 78 | 88 | $2,640 | $960.66 | 36.4% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2022 | 39 | 78 | $26,964 | $20,921 | 77.6% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 39 | 39 | $52,672 | $14,484 | 27.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 93 | 96 | $57,252 | $14,086 | 24.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 82 | 117 | $42,770 | $10,992 | 25.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 64 | 64 | $31,710 | $7,517 | 23.7% |
| 93241 | Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2022 | 15 | 15 | $4,289 | $2,942 | 68.6% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2022 | 15 | 60 | $10,448 | $2,911 | 27.9% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2022 | 52 | 55 | $11,490 | $2,771 | 24.1% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2022 | 13 | 13 | $7,509 | $2,050 | 27.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 74 | 77 | $3,270 | $810.56 | 24.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 166 | 295 | $111,510 | $26,918 | 24.1% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2021 | 109 | 113 | $67,913 | $16,652 | 24.5% |
| 78452 | Nuclear medicine study of vessels of heart using drugs or exercise multiple studies | Office | 2021 | 38 | 38 | $53,922 | $14,900 | 27.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 40 | 40 | $19,760 | $5,217 | 26.4% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2021 | 28 | 54 | $19,116 | $5,091 | 26.6% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2021 | 14 | 52 | $9,256 | $2,522 | 27.2% |
About Dr. David Perloff, MD
Dr. David Perloff, MD is a Cardiovascular Disease healthcare provider based in Fort Lauderdale, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548221237.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Perloff, MD has received a total of $477,330 in payments from pharmaceutical and medical device companies, with $25,521 received in 2024. These payments were reported across 743 transactions from 35 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($385,449).
As a Medicare-enrolled provider, Perloff has provided services to 2,167 Medicare beneficiaries, totaling 3,186 services with total Medicare billing of $341,834. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Fort Lauderdale, FL
- Active Since 03/31/2006
- Last Updated 07/21/2022
- Taxonomy Code 207RC0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1548221237
Products in Payments
- PRALUENT (Drug) $129,267
- JARDIANCE (Drug) $110,697
- NEXLIZET (Drug) $93,093
- PRALUENT (Biological) $36,807
- PRALUENT ALIROCUMAB INJECTION (Biological) $32,320
- Repatha (Biological) $26,330
- ELIQUIS (Drug) $23,444
- VERQUVO (Drug) $7,001
- NEXLETOL (Drug) $5,008
- MULTAQ (Drug) $1,592
- FARXIGA (Drug) $1,017
- LifeVest (Device) $484.84
- AtriCure AtriClip LAA Exclusion System (Device) $397.77
- AtriCure Cryosurgical System (Device) $370.94
- Kerendia (Drug) $320.60
- ENTRESTO (Drug) $296.87
- XARELTO (Drug) $244.83
- WATCHMAN (Device) $238.80
- Bioprosthetic Mitral Valve (Device) $210.22
- Mosaic (Device) $159.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Fort Lauderdale
Joel Gellman, Md, MD
Cardiovascular Disease — Payments: $284,701
Cardiovascular Disease $284,701
Karan Munuswamy, Md, MD
Cardiovascular Disease — Payments: $108,087
Cardiovascular Disease $108,087
Dr. Joshua Larned, M.d, M.D
Cardiovascular Disease — Payments: $41,848
Cardiovascular Disease $41,848
Ronald Pachon, M.d, M.D
Cardiovascular Disease — Payments: $37,567
Cardiovascular Disease $37,567
Joshua Purow, Md, MD
Cardiovascular Disease — Payments: $33,217
Cardiovascular Disease $33,217
Ricardo Vicuna, M.d, M.D
Cardiovascular Disease — Payments: $4,699
Cardiovascular Disease $4,699